Gynecologic Cancer: Education, Tools, and Resources to Optimize Patient Care

Review the latest strategies for optimizing care of patients with gynecologic cancers including discussion of new approvals predictive biomarkers and key clinical trials in cervical endometrial and ovarian cancers. Learn from the experts with focused commentaries a module with downloadable slides and 2 Interactive Decision Support Tools that provide personalized management recommendations for treatment selection.

Share

Program Content

Activities

CC: Advances
Advances and Recent Approvals for Immunotherapy and Targeted Therapies in Cervical Cancer
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: February 18, 2022

Expires: February 17, 2023

New Hope for PROC
Why I Have Renewed Hope for Better Treatment of Platinum-Resistant Ovarian Cancer
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: August 11, 2022

Expires: August 10, 2023

Activities

GynOnc Expert Insight
Key Advances in Gynecologic Cancers: Expert Insight for Incorporating New Clinical Evidence
Text Module
Congratulations: You achieved a completion on 04/09/2022

Released: May 13, 2022

Expires: May 12, 2023

Slides: GynOnc Expert Insight
Advances in Gynecologic Cancers: Expert Insight for Incorporating New Clinical Evidence
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: May 13, 2022

Expires: May 12, 2023

Activities

Treatment Selection for Ovarian Cancer
Interactive Decision Support Tool: Treatment Selection for Patients With Advanced Ovarian Cancer
Tool
Congratulations: You achieved a completion on 04/09/2022

Released: August 05, 2022

Expires: August 04, 2023

Treatment Selection for Advanced Endometrial Cancer
Interactive Decision Support Tool: Treatment Selection for Patients With Advanced Endometrial Cancer
Tool
Congratulations: You achieved a completion on 04/09/2022

Released: September 13, 2022

Expires: September 12, 2023

Provided by

ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

GlaxoSmithKline

Merck Sharp & Dohme Corp.

Regeneron Pharmaceuticals, Inc. and Sanofi Genzyme